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According to these ﬁndings, treatment with 160mg valsartan/
25mg HCTZ totally dominates and it should be preferable. Sen-
sitivity analysis conﬁrmed the results from this base case.
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OBJECTIVES: Hypertension is a highly prevalent risk factor for
cardiovascular disease (CVD), which affects approximately 50
million Americans. The outcome data from several clinical trials
and meta-analyses prove that new and old classes of antihyper-
tensive drugs provide similar reductions of cardiovascular mor-
bidity and mortality. The purpose of this study was to compare
the costs associated with the prescription of ﬁrst-line anti-
hypertensive agents in United States (US). METHODS: A cost-
minimization analysis was performed. A decision analysis model
was developed to compare the ﬁve alternative interventions:
chlorthalidone, propranolol, amlodipine, enalapril and losartan.
Clinical inputs were derived from randomized controlled trials
and cost data from 2004 Red Book and Centers for Medicare &
Medicaid Services. The evaluation of the cost of managing mild-
to-moderate hypertension includes the cost of drug therapy,
monitoring, treating side-effects, poor compliance and switching.
All costs were calculated from a health system’s perspective, in
2004 $US. Future costs and clinical beneﬁts were discounted at
5%. The time horizon was 5 years. RESULTS: The total cost to
achieve and maintain hypertension control in US setting was
$2194.42, $3181.79, $3566.36, $2885.69 and $3747.57 for
chlorthalidone, propranolol, amlodipine, enalapril and losartan
respectively. The drug acquisition cost was 27.54%, 51.28%,
58.18%, 47.83%, and 61.55% respectively. Sensitivity analysis
tested the effect of modifying the prices of the antihypertensive
agents and laboratory monitoring, the doses of the alternative
drugs and the compliance rate on the economic endpoints and
conﬁrmed the superiority of chlorthalidone. CONCLUSIONS:
In patients with mild-to-moderate hypertension in US, treatment
costs to prevent CVD are much lower with chlorthalidone than
with the other ﬁrst-line antihypertensive agents.
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Despite therapeutic advances, High Blood Pressure (HBP)
remains a health issue in Western countries. Few programs have
sought to improve physician-patient relationship and the effect
of educating HBP patients. CV@Goal is a French educational
programme (2002 to 2003) aimed at training physicians to
educate HBP patients. OBJECTIVES: Assessing the impact of
CV@Goal on HBP patients and physicians. METHODS: A 6-
month before-after comparison of physician and HBP patient
populations. Four HBP patients per GPs were included. GPs were
trained to educate HBP patients and included four new HBP
patients. RESULTS: In total, 1208 HBP patients and 308 physi-
cians completed the “before” questionnaire, and after training
512 new patients and 169 physicians completed the “after” ques-
tionnaire. According to GPs, there were in both phases “impor-
tant” or “insurmountable difﬁculties” concerning patient seden-
tary lifestyle (40%), diet compliance (60%) and alcohol (75%).
The proportion of GPs who considered patient knowledge to be
“good” or “very good” increased for: general issues (22% to
38%), the disease natural history (8% to 14%), risks (29% to
49%), complication prevention (13% to 24.5%) and alarm
symptoms (21% to 35%); the proportion also increased for
patient awareness of the importance of smoking cessation (69%
to 77%) and special dieting (52% to 67%). Changes in patients’
blood pressure were not signiﬁcant. Most patients believed
smoking, diabetes, alcohol, hypercholesterolemia, treatment
compliance, obesity, age, heredity and diet could alter blood
pressure; knew HBP could relate to heart, brain, arteries, eyes,
kidneys complications; that smoking cessation, weight loss,
physical exercise and salt reduction could improve HBP. After
CV@Goal, improvements were observed in patient knowledge
about the importance of weight loss, physical exercise and salt
consumption. Nevertheless, most patients declare they have not
changed lifestyle since the HBP diagnosis. CONCLUSION:
CV@Goal had an impact on patient knowledge about HBP, but
not on lifestyle and BP.
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OBJECTIVES: Hypertensive patients with cardiovascular (CV)
disease or diabetes are at a particularly high CV risk. LDL-
cholesterol (cLDL) levels are an important CV risk factor and
total cholesterol/cHDL (TC/HDL) ratio is also related to car-
diovascular risk. Although HDL-cholesterol (cHDL) is a protec-
tive factor, available therapeutic strategies are not effective
enough. The objective of this study is to compare cLDL, cHDL
and TC/HDL between two groups: patients with previous CV
disease/diabetes and those without it in a hypertensive popula-
tion from a programme for CV risk control. METHODS: A total
of 5094 subjects from primary care centres in Spain were retro-
spectively studied. Levels of cLDL, cHDL and TC/HDL were
compared for the above mentioned groups by Student t test for
independent samples. RESULTS: There were 41.4% men. Mean
age 66.3 years. Average TC levels were: 214.4mg/dL; cLDL:
141.9mg/dL; cHDL: 45.5mg/dL and TC/HDL: 4.98. Levels of
cLDL were signiﬁcantly lower for those with CV disease/dia-
betes: 148.6mg/dL (SD 32.8) vs. 132.3mg/dL (SD 35); p <
0.0001. Similarly, Levels of cHDL were signiﬁcantly lower 
for those with CV disease/diabetes: 47.1mg/dL (SD 12.5) vs.
43.1mg/dL (SD 11.4): p < 0.0001. There were no signiﬁcant dif-
ferences of CT/HDL ratio between groups. CONCLUSIONS: In
a population of treated hypertensives, cLDL levels are lower for
those with previous CV disease/diabetes, which is appropriate
taking into account their higher cardiovascular risk. On the con-
trary cHDL levels are lower in the group at highest risk. There
is a wide room for improvement of cardiovascular risk in hyper-
tensive patients with previous CV disease or diabetes, by increas-
ing HDL.
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OBJECTIVE: The aim of this study was to analyze the out-
hospital cardiovascular drug utilization in the city of Nis. The
prevalence of cardiovascular disease is high in Serbia. Analysis
of cardiovascular drugs utilization in a population is the basis
for the assessment of cardiovascular pharmacotherapy.
METHODS: Using the ATC/DDD methodology, we analyzed the
utilization of cardiovascular drugs dispensed on prescription in
Nis region in 2003–2004. A retrospective study on cardiovascu-
lar drugs utilization according to ATC classiﬁcation, was con-
ducted on the basis of data received from Central City Pharmacy
Nis. RESULTS: Results were presented in DDD/1000 inhabi-
tants/day. The most frequently prescribed drug in 2003–2004
was Enalapril (32.16: 41.71 DDD/1000 inhabitants/day. Besides,
consumption of other ACE inhibitors was small (2.94 :6.48
DDD/1000 inhabitants/day). The next most commonly used
drugs were selective beta blockers (atenolol-8.48DDD/1000
inhabitants/day; metoprolol 5.85 DDD/1000 inhabitants/day) in
2003. The use of amlodipin had a signiﬁcant increase in 2004
(10.21 DDD/1000 inhabitants/day: 6.41 DDD/1000 inhabi-
tants/day). Marginal use of diuretics was detected (4.48
DDD/1000 inhabitants/day: 5.19 DDD/1000 inhabitants/day).
CONCLUSION: The present analysis for 2003–2004 pointed to
therapeutic irrationalities which could be overcome with educa-
tion concerning cardiovascular drugs consumption in Nis region
(south-east Serbia).
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OBJECTIVES: To analyse the utilisation of antihypertensive
drugs within Slovakia between 2000 and 2004 and to asses 
the economic consequences of antihypertensive medications.
METHODS: For 2000–2004, the data about consumption of
drugs for cardiovascular disease were collected, in accordance
with the Anatomic Therapeutic Chemical classiﬁcation (ATC:
C01- C10) and Deﬁned Daily Dose (DDD) measurement unit.
This analysis focused on the situation in antihypertensive med-
ication in more detail. Data of wholesalers, who are legally
obliged provide this information to the SUKL, was used for the
analysis. RESULTS: A signiﬁcant increase in the medication of
cardiovascular disease (in 2000 (290.27), in 2002 (376.30) and
in 2004 (388.06) in term of DDD/1000/day can be seen from
this analysis. The results show that the consumption (in term of
DDD/1000/day) of ß-blockers was (in 2000 (32.04), in 2002
(41.91) and in 2004 (42.78)), ACE inhibitors (in 2000 (57.01),
in 2002 (81.86) and in 2004 (88.79)), Ca-blockers (in 2000
(39.72), in 2002 (55.42) and in 2004 (63.25)), diuretics (in 2000
(28.20), in 2002 (32.82) and in 2004 (31.67)), peripheral
vasodilators (in 2000 (20.89), in 2002 (22.12) and in 2004
(19.63)), vasoprotectives (in 2000 (33.89), in 2002 (41.67) and
in 2004 (34.23)), serum lipid reducing agents (in 2000 (12.79),
in 2002 (22.18) and in 2004 (31.50)). In ﬁnancial terms, the 
consumption of ß-blockers in 2000 (€7,024,000) and 2004
(€10,515,000), ACE inhibitors in 2000 (€18,714,000) and 
2004 (€32,290,000), Ca-blockers in 2000 (€16,971,000) and
2004 (€19,454,000), diuretics in 2000 (€1,609,000) and 2004
(€2,478,000) can be seen from this study. CONCLUSIONS:
Inseparable components of the Slovak drug policy must be
viewed realistically with regard to the antihypertensive drugs’
consumption. Adherence to principles of antihypertensive treat-
ment’s guidelines lead to fundamental short and long term ﬁnan-
cial savings within health care systems.
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OBJETIVE: To estimate the cost-effectiveness of 160mg valsar-
tan as an alternative treatment for systemic arterial hypertension
as compared with daily doses of 100mg losartan and 80mg
telmisartan using a pharmaco-economic analysis. METHOD-
OLOGY: The study was based on a literature review and expert
opinion in two phases: the ﬁrst was a literature search to deter-
mine effectiveness expressed as a reduction of mm Hg; the
second consisted of a cost-effectiveness analysis. The model used
the Mexican Health System perspective. Only direct medical
costs were included. Data costs were obtained from published
lists of unitary costs for the Health Sector. RESULTS: Following
treatment with 160mg valsartan and 100mg losartan for 4
weeks, the mean sitting diastolic blood pressure (MSDBP) was 
-10.5mmHg and -9.7mmHg respectively. The difference was
not signiﬁcantly signiﬁcant. In the case of valsartan versus 80mg
telmisartan, valsartan proved more effectiveness, showing a
reduction in systolic and diastolic pressure of -18.6 and 
-12.1mmHg respectively as compared with reductions of -10.8
and -8.4mmHg for telmisartan. The cost analysis did not show
any differences in terms of other medical interventions but there
was a difference in the cost of the drugs. The monthly cost per
patient treated was the lowest with 160mg valsartan at $246.67
Mexican pesos (US$22.42), as compared with $695.60 Mexican
pesos (US$63.23) for 100mg losartan and $469.29 ($42.66) for
80mg telmisartan. CONCLUSIONS: Treatment with 160mg
valsartan is the least costly with at least the same efﬁcacy in
reducing arterial pressure as 100mg daily dose of losartan. In
the case of 80mg telmisartan, 160mg valsartan was more effec-
tive with a lower cost. It has been shown that 160mg valsartan
is the preferred treatment in terms of pharmaco-economic para-
meters compared with the other options studied. Sensitivity
analysis conﬁrmed the results obtained in the base case.
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OBJECTIVES: To investigate if there are differences in the per-
sistence and compliance to therapy depending on the antihyper-
tensive drug class prescribed ﬁrst (index drug). METHODS:
Prescription claims data were analysed for the 2000 to 2003 time
period. Index prescriptions were determined for: ACE-inhibitors
(ACEi), angiotensin receptor blockers (ARB), beta blockers
(BETA), calcium channel blockers (CCB), and diuretics (DIU).
Patients regarded as newly diagnosed (i.e., without any antihy-
pertensive medication 180 days before the index time point) with
a follow-up of at least 360 days were included in the study. Per-
sistence rates (percentage of beneﬁciaries on continuous therapy
with the index drug at 180 and 360 days) were calculated for
each drug class. Compliance was determined in terms of the med-
ication possession ratio (MPR) for 180 and 360 days (dispensed
supply in deﬁned daily dose (DDD) within 180 and 360 days
